NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. [1]
The move after the bell was small, but MRK’s two-day run has been anything but: the stock is coming off a sharp gain on Monday (Dec. 22) and is trading within reach of its 52-week high—a setup that often makes the next session more about “what’s next” than what just happened. [2]
Below is what investors and traders will want on their radar before the market opens Wednesday (Dec. 24, 2025)—including why Merck has been bid up lately, what today’s headlines say about sentiment, and why tomorrow’s session may behave differently than a typical weekday.
MRK after-hours recap: close near $105, a mild dip after the bell
Merck’s $105.04 close left the stock up about 0.3% on the day, while after-hours activity showed a slight pullback into the $104.8 area. [3]
Two details matter here:
- After-hours trading is thinner by nature. Small shifts can reflect limited liquidity rather than a true change in fundamentals.
- MRK is hovering close to a 52-week high. Merck’s high-water mark has been cited around $105.84, which can act as a near-term psychological level for momentum traders. [4]
Why Merck stock has been in focus this week: TrumpRx pricing headlines + FDA “fast-track” tailwinds
Even though there wasn’t a single blockbuster Merck-specific announcement late Tuesday, investors have been digesting two major themes that broke in the last several days and continue to shape the MRK narrative.
1) TrumpRx / drug-pricing agreement: what Merck committed to—and why the market didn’t panic
On Dec. 19, the White House announced new agreements with nine drugmakers (including Merck) tied to a “most-favored-nation” pricing framework and expanded direct-to-consumer pricing via TrumpRx. [5]
Reuters’ reporting added color on why the initial market reaction across pharma was relatively constructive: investors appeared to view the agreements as reducing the immediate threat of tariffs and other uncertainties, while questioning how large the economic hit would be in practice. [6]
For Merck specifically, the key takeaways are concrete:
- Merck said it will sell Januvia, Janumet, and Janumet XR directly to U.S. consumers at roughly 70% off list prices (important context: these products are also expected to face generic competition next year, which influences how investors model their future contribution). [7]
- The White House fact sheet highlighted an example price change: Januvia from $330 to $100 via TrumpRx for direct purchasers. [8]
What this means for MRK stock going into tomorrow: The market appears to be treating the pricing headlines as a mix of policy risk and headline management—with Merck’s exposure partly offset by product lifecycle realities (notably the approaching generic window for some diabetes drugs) and by Merck’s broader portfolio led by oncology.
2) FDA “National Priority Review Vouchers”: a catalyst investors are taking seriously
Merck also benefited from a separate policy/regulatory narrative: Reuters reported the U.S. FDA granted national priority review vouchers to Merck for two programs—an experimental cholesterol pill (enlicitide) and a cancer therapy (sac‑TMT). The program can compress review timelines dramatically (Reuters described a reduction from roughly 10–12 months to 1–2 months). [9]
An earlier Reuters report also described why this matters commercially:
- Enlicitide could become the first oral PCSK9 inhibitor, potentially competing with established injectable PCSK9 drugs, with an FDA filing targeted around April (per Reuters). [10]
- sac‑TMT is an antibody-drug conjugate being tested across multiple cancers, with submission projected later (Reuters referenced late 2026). [11]
Why it matters for tomorrow: This kind of “faster path to decision” headline can support valuation and sentiment, especially when a stock is already trending higher. It’s also the type of catalyst that can resurface on quiet holiday sessions, when fewer competing stories are in the tape.
Today’s “forecast” picture: where analysts see MRK next, and what the street is implying
A lot of the “today” content around Merck was not a new corporate development—it was market framing: price targets, ratings roundups, and positioning signals.
Wall Street targets: higher ceilings, but consensus still reads as cautious
A MarketBeat roundup published Tuesday cited a cluster of recent analyst actions and an overall stance that can be summarized as: upside exists, but conviction isn’t unanimous.
Highlights from that compilation include:
- BMO upgrading to Outperform and raising its target dramatically (MarketBeat cited $130).
- Wells Fargo moving to Overweight with a cited target of $125.
- Scotiabank raising its target to $120. [12]
MarketBeat also reported a blended view: an average rating around “Hold” and an average price target near $110.13. [13]
How to interpret that for tomorrow morning: When a stock is near a 52-week high while the consensus is still “Hold,” it often sets up a tug-of-war between:
- momentum buyers expecting breakout continuation, and
- valuation-disciplined investors waiting for fresh fundamental proof (earnings, guidance, trial data, FDA decisions).
Options flow: “whales” skewed slightly bearish—worth noting, not overreacting
Benzinga’s options-focused piece published Tuesday flagged what it described as “whale” activity that leaned modestly bearish by trade count (their breakdown: 53% bearish vs. 46% bullish across 13 detected trades). It also reported more premium concentrated in puts than calls in the observed set. [14]
They also pointed to notable strike clustering: a “price territory” from $90 to $110 over the past three months based on their scan. [15]
Practical takeaway for the Dec. 24 open: Options flow can signal hedging near highs—especially into holiday trading—but it’s not a single-direction forecast. With MRK around $105, that $90–$110 band reads less like a prediction and more like a map of where traders have been paying for insurance (puts) and upside exposure (calls).
The calendar: what to watch before Wednesday’s open (Dec. 24, 2025)
1) Tomorrow is a holiday-style session—expect different market “texture”
Wednesday Dec. 24 is Christmas Eve, and U.S. equity markets typically run on a shortened schedule.
The NYSE calendar shows an early close (1:00 p.m. ET) on Christmas Eve (with certain products closing earlier). [16]
Why that matters for MRK traders:
- thinner liquidity can amplify moves on relatively modest headline flow,
- spreads can widen, and
- “breakout” or “breakdown” signals can be less reliable than on normal-volume days.
2) Pre-market macro data could nudge sentiment (even for a pharma name)
Merck isn’t as macro-sensitive as banks or high-multiple tech, but index tone still matters—especially when markets are near record levels.
The New York Fed’s economic calendar lists several Dec. 24 releases, including Advance Durable Goods and the Philadelphia Fed Non-Manufacturing Survey at 8:30 a.m. ET, and the Weekly Economic Index at 11:30 a.m. ET. [17]
Also, Tuesday’s macro backdrop wasn’t entirely rosy: Reuters reported U.S. consumer confidence weakened in December, reflecting job/income worries. [18]
3) Next major Merck-specific “hard catalyst”: earnings date
Merck’s investor relations events calendar lists the Q4 2025 earnings call on Feb. 3, 2026. [19]
That’s not “tomorrow morning” relevant—but it helps explain current positioning: when the next earnings checkpoint is weeks away, price action can be driven more by policy headlines and pipeline/regulatory updates than by near-term financial revisions.
Dividend and shareholder return angle: still part of the MRK bid
Merck previously announced a quarterly dividend of $0.85 per share for Q1 2026, payable Jan. 8, 2026 to shareholders of record Dec. 15, 2025. [20]
Why this remains relevant going into the Dec. 24 open:
- dividend credibility can attract defensive inflows when markets are volatile,
- and it supports “total return” narratives for long-term holders, even when the stock chops sideways near highs.
What to watch at the open: a quick MRK checklist for Dec. 24
Here’s a tight checklist of what matters most before the bell Wednesday:
- After-hours direction and volume: Does MRK stabilize back toward ~$105 or continue drifting lower in thin trade? [21]
- Headline tape on TrumpRx: Any clarifications, implementation details, or pushback that changes how investors model the pricing impact. [22]
- Regulatory chatter: Follow-ons to the FDA priority voucher story—fast-track frameworks can produce secondary headlines, especially if other companies react or if more details emerge. [23]
- Market mood and liquidity: Early-close dynamics can create “air pockets” where moves overshoot and then mean-revert. [24]
- Macro releases at 8:30 a.m. ET: Durable goods / Philly Fed services data can swing futures and set the tone even for defensive names. [25]
Bottom line
Merck stock’s after-hours dip Tuesday looks more like positioning noise than a new verdict on the company. The bigger story is that MRK is trading near a 52-week high while investors weigh (1) a high-profile U.S. pricing agreement tied to TrumpRx, and (2) a potentially meaningful FDA “fast-track” tailwind for two pipeline assets.
With Christmas Eve’s early close likely to reduce liquidity, the Dec. 24 session could be driven less by deep fundamental re-rating and more by headline sensitivity and market mechanics.
This article is for informational purposes only and is not investment advice.
References
1. www.google.com, 2. stockanalysis.com, 3. www.google.com, 4. www.marketbeat.com, 5. www.whitehouse.gov, 6. www.reuters.com, 7. www.reuters.com, 8. www.whitehouse.gov, 9. www.reuters.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.marketbeat.com, 13. www.marketbeat.com, 14. www.benzinga.com, 15. www.benzinga.com, 16. www.nyse.com, 17. www.newyorkfed.org, 18. www.reuters.com, 19. www.merck.com, 20. www.merck.com, 21. www.google.com, 22. www.reuters.com, 23. www.reuters.com, 24. www.nyse.com, 25. www.newyorkfed.org
